DHR vs VRTV: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Veritiv Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
VS
Veritiv Corporation · Industrials
$169.99
-43.3% upside to fair value
Grade D
QuantHub Verdict
DHR has more upside to fair value
(+8.9%).
VRTV trades at a lower forward P/E
(7.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
VRTV |
| Current Price |
$177.17 |
$169.99 |
| Fair Value Estimate |
$192.90 |
$96.38 |
| Upside to Fair Value |
+8.9%
|
-43.3%
|
| Market Cap |
$125.4B |
$2.3B |
| Forward P/E |
34.1x
|
7.1x
|
| EV / EBITDA |
20.8x
|
5.4x
|
| Price / Sales |
5.1x
|
0.3x
|
| Price / FCF |
23.7x
|
10.0x
|
| Revenue Growth YoY |
+3.7%
|
-19.0%
|
| Gross Margin |
60.7%
|
22.7%
|
| Operating Margin |
21.0%
|
5.9%
|
| Return on Equity |
7.1%
|
48.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.22%
|
9.99%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Veritiv Corporation operates as a distributor primarily in packaging, facility solutions, and print markets, with a business quality characterized by scale and network density rather than proprietary products or pricing power. The company has undergone significant transformation under CEO Salvatore A. Abbate, including a take-private transaction by Clayton, Dubilier & Rice in 2023 and a strategic…
Accumulation Zones
| Metric |
DHR |
VRTV |
| Zone Low |
$144.68 |
$72.28 |
| Zone High |
$163.97 |
$81.92 |
| In Buy Zone? |
No
|
No
|